ArticleJournal of managed care & specialty pharmacy2024

Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.

Scott F Huntington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.